Seeing Is Believing
Currently out of the existing stock ratings of Christopher Raymond, 384 are a BUY (78.69%), 99 are a HOLD (20.29%), 5 are a SELL (1.02%).
Analyst Christopher Raymond, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 49.76% that have a potential upside of 39.39% achieved within 251 days.
Christopher Raymond’s has documented 963 price targets and ratings displayed on 40 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on BMRN, Biomarin Pharmaceutical at 20-Feb-2025.
Analyst best performing recommendations are on ALXO (ALX ONCOLOGY HOLDINGS ).
The best stock recommendation documented was for DCPH (DECIPHERA PHARMACEUTICALS LLC) at 5/31/2018. The price target of $35 was fulfilled within 4 days with a profit of $9.28 (36.08%) receiving and performance score of 90.2.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$214
$4.99 (2.39%)
$221
1 months ago
(03-Feb-2025)
22/24 (91.67%)
$23.86 (12.55%)
449
Buy
$217
$7.99 (3.82%)
$211
1 months ago
(03-Feb-2025)
0/3 (0%)
$26.86 (14.13%)
Buy
$220
$10.99 (5.26%)
$195
1 months ago
(03-Feb-2025)
11/12 (91.67%)
$29.86 (15.70%)
342
Hold
$190
$-19.01 (-9.10%)
$200
1 months ago
(03-Feb-2025)
15/15 (100%)
$-0.14 (-0.07%)
259
Buy
$215
$5.99 (2.87%)
$205
1 months ago
(03-Feb-2025)
10/13 (76.92%)
$24.86 (13.07%)
327
Which stock is Christopher Raymond is most bullish on?
Which stock is Christopher Raymond is most reserved on?
What Year was the first public recommendation made by Christopher Raymond?